CoChat

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Simvastatin and fenofibrate are both commonly used lipid‐regulating agents with distinct mechanisms of action, and their coadministration may be an attractive treatment for some patients with dyslipidemia. A 2‐period, randomized, open‐label, crossover study was conducted in 12 subjects to determine if fenofibrate and simvastatin are subject to a clinically relevant pharmacokinetic interaction at steady state. In treatment A, subjects received an 80‐mg simvastatin tablet in the morning for 7 days. In treatment B, subjects received a 160‐mg micronized fenofibrate capsule in the morning for 7 days, followed by a 160‐mg micronized fenofibrate capsule dosed together with an 80‐mg simvastatin tablet on days 8 to 14. Because food increases the bioavailability of fenofibrate, each dose was administered with food to maximize the exposure of fenofibric acid. The steady‐state pharmacokinetics (AUC 0–24h, C max, and t max) of active and total HMG‐CoA reductase inhibitors, simvastatin acid, and simvastatin were determined following simvastatin administration with and without fenofibrate. Also, fenofibric acid steady‐state pharmacokinetics were evaluated with and without simvastatin. The geometric mean ratios (GMRs) for AUC 0–24h (80 mg simvastatin [SV] + 160 mg fenofibrate)/(80 mg simvastatin alone) and 90% confidence intervals (CIs) were 0.88 (0.80, 0.95) and 0.92 (0.82, 1.03) for active and total HMG‐CoA reductase inhibitors. The GMRs and 90% CIs for fenofibric acid (80 mg SV + 160 mg fenofibrate/160 mg fenofibrate alone) AUC 0–24h and C max were 0.95 (0.88, 1.04) and 0.89 (0.77, 1.02), respectively. Because both the active inhibitor and fenofibric acid AUC GMR 90% confidence intervals fell within the prespecified bounds of (0.70, 1.43), no clinically significant pharmacokinetic drug interaction between fenofibrate and simvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1177/0091270004268044

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 4

  1. Scandinavian Simvastatin Survival Group, 1994, Randomised trial of cholesterol lowering in 4444 patients with coronoary heart disease the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
  2. 10.1001/archinte.1996.00440170097011 · DOI · Paper page
  3. 10.1016/s0009-9236(03)00052-3 · DOI · Paper page
  4. 2003, Crestor® product information

Cited by

See all 97

Metadata

Authors
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., Hartford, A., Vega, J. M., & Paolini, J. F.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Bergman, Arthur J.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2004-09
Volume
44
Issue
9
Pages
1054-1062
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2053536280
Cited by
97
References
27
Citations by year
2024: 2 · 2023: 2 · 2022: 1 · 2021: 1 · 2019: 3 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 8
FWCI
10.14
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
simvastatin, fenofibrate, drug-drug interactions, pharmacokinetic interactions, statins, fenofibric acid, lipid-lowering therapy, dyslipidemia, crossover design, steady-state pharmacokinetics, 90% confidence interval
MeSH terms
Adolescent, Adult, Hypolipidemic Agents, Biotransformation, Blood Cell Count, Drug Interactions, Electrocardiography, Female, Half-Life, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Microsomes, Liver, Middle Aged, Fenofibrate, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve, Simvastatin, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans. https://app.cochat.ai/papers/10.1177/0091270004268044
The paper
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., Hartford, A., Vega, J. M., & Paolini, J. F. (2004). Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270004268044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.